Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 2,485 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 2,485 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $27.52, for a total value of $68,387.20. Following the sale, the insider now owns 75,294 shares of the company’s stock, valued at approximately $2,072,090.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total transaction of $106,684.76.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $143,052.00.

Akero Therapeutics Price Performance

NASDAQ AKRO traded up $0.32 during trading hours on Wednesday, reaching $26.96. The company’s stock had a trading volume of 485,803 shares, compared to its average volume of 933,663. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The stock has a market cap of $1.86 billion, a PE ratio of -8.43 and a beta of -0.26. The company’s 50-day moving average is $26.22 and its two-hundred day moving average is $23.95. Akero Therapeutics, Inc. has a fifty-two week low of $11.25 and a fifty-two week high of $53.00.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.09. Analysts forecast that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Wolfe Research initiated coverage on shares of Akero Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Akero Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $41.13.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its stake in shares of Akero Therapeutics by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 425,545 shares of the company’s stock worth $9,936,000 after purchasing an additional 6,115 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Akero Therapeutics by 256.5% in the fourth quarter. BNP Paribas Financial Markets now owns 212,212 shares of the company’s stock valued at $4,955,000 after buying an additional 152,691 shares during the last quarter. UBS Group AG lifted its stake in shares of Akero Therapeutics by 356.1% during the fourth quarter. UBS Group AG now owns 266,386 shares of the company’s stock valued at $6,220,000 after buying an additional 207,983 shares during the period. Quest Partners LLC acquired a new stake in Akero Therapeutics during the fourth quarter worth approximately $75,000. Finally, Rafferty Asset Management LLC grew its stake in Akero Therapeutics by 146.2% in the 4th quarter. Rafferty Asset Management LLC now owns 451,832 shares of the company’s stock worth $10,550,000 after acquiring an additional 268,335 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.